TABLE 3.
Univariate and multivariate analyses of overall survival
| Variables | Total no. | Univariate | Multivariate | |||
|---|---|---|---|---|---|---|
| Median (months) | 95% CI of median | p value | HR (95% CI) | p value | ||
| Age (years) | 0.510 | |||||
| <70 | 21 | 12.9 | 9.7–16.1 | |||
| ≥70 | 23 | 14.9 | 4.4–25.4 | |||
| Sex | 0.042 | |||||
| Male | 12 | 5.2 | 0.1–13.8 | 0.45 (0.12–1.67) | 0.233 | |
| Female | 32 | 14.9 | 5.8–24.0 | Reference | ||
| ECOG PS | 0.002 | |||||
| 0–1 | 30 | 19.8 | 9.3–30.4 | 0.32 (0.14–0.74) | 0.007 | |
| 2–4 | 14 | 7.8 | 0.1–18.5 | Reference | ||
| Smoking status | 0.049 | |||||
| Ever | 9 | 5.2 | 4.9–5.5 | Reference | ||
| Never | 35 | 15.3 | 10.3–20.3 | 0.61 (0.15–2.43) | 0.483 | |
| Mutation type | 0.281 | |||||
| Del19 | 7 | 22.4 | 15.1–29.8 | |||
| L858R | 8 | 2.9 | 0.4–5.3 | |||
| L858R/Del19 | 24 | 12.9 | 8.2–17.6 | |||
| Others | 5 | 5.1 | 0.1–17.3 | |||
| Lung metastasis | 0.052 | |||||
| Yes | 21 | 12.7 | 6.7–18.8 | Reference | ||
| No | 23 | 15.3 | 3.2–27.3 | 0.42 (0.19–0.92) | 0.029 | |
| Liver metastasis | 0.105 | |||||
| Yes | 4 | 2.0 | 0.1–4.5 | |||
| No | 40 | 13.2 | 9.4–17.0 | |||
| Brain metastasis | 0.642 | |||||
| Yes | 10 | 12.9 | 8.0–17.7 | |||
| No | 34 | 12.7 | 5.8–19.6 | |||
| Bone metastasis | 0.475 | |||||
| Yes | 21 | 14.9 | 7.1–22.7 | |||
| No | 23 | 12.7 | 8.0–17.4 | |||
| Pleural metastasis | 0.242 | |||||
| Yes | 26 | 12.7 | 8.9–16.5 | |||
| No | 18 | 15.3 | 4.9–25.6 | |||
| T790M ratio | 0.773 | |||||
| ≥Median | 21 | 5.2 | 0.1–15.6 | |||
| <Median | 20 | 19.6 | 12.5–26.6 | |||
| Unknown | 3 | 12.9 | 0.1–30.2 | |||
| TKI | ||||||
| Gefitinib | 21 | 12.2 | 6.0–18.3 | 0.002 | 0.61 (0.22–1.74) | 0.355 |
| Erlotinib | 6 | 2.2 | 0.1–6.0 | Reference | ||
| Afatinib | 12 | 22.4 | 1.7–43.2 | 0.23 (0.07–0.81) | 0.022 | |
| Osimertinib | 5 | 23.0 | 8.9–37.1 | 0.21 (0.06–0.83) | 0.025 | |
| Response | <0.0001 | – | ||||
| PR | 14 | 22.4 | 8.0–36.8 | |||
| SD | 9 | 16.4 | 13.1–19.7 | |||
| PD | 15 | 4.7 | 3.1–6.3 | |||
| NA | 6 | 1.2 | 0.1–2.7 | |||
Abbreviations: CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; NA, not assessed; PD, progressive disease; PR, partial response; SD, stable disease; TKI, tyrosine kinase inhibitor.